Y-mAbs Therapeutics Inc YMAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if YMAB is a good fit for your portfolio.
News
-
Y-mAbs to Present at 2024 ASCO Annual Meeting
-
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
-
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
-
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
-
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
-
Y-mAbs Therapeutics New Drug Application Gets FDA Clearance
Trading Information
- Previous Close Price
- $15.29
- Day Range
- $14.28–15.46
- 52-Week Range
- $4.60–20.90
- Bid/Ask
- $14.34 / $17.38
- Market Cap
- $649.65 Mil
- Volume/Avg
- 365,385 / 391,068
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.87
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 100
- Website
- https://www.ymabs.com
Comparables
Valuation
|
Metric
|
YMAB
|
CLDX
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.61 | 4.82 | 0.77 |
Price/Sales | 7.87 | 260.58 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
YMAB
|
CLDX
|
VOR
|
|---|---|---|---|
Quick Ratio | 5.02 | 13.69 | 8.81 |
Current Ratio | 5.52 | 13.87 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
YMAB
CLDX
VOR
Profitability
|
Metric
|
YMAB
|
CLDX
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −8.24% | −30.49% | −41.83% |
Return on Equity (Normalized) | −10.52% | −33.19% | −51.69% |
Return on Invested Capital (Normalized) | −13.95% | −32.85% | −47.03% |
Return on Assets
YMAB
CLDX
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yjpchvprj | Qszb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fgcrcmk | Dkmyy | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pxfrgxyf | Hzvylg | $97.8 Bil | |
MRNA
| Moderna Inc | Nfzpxffzz | Jvfj | $38.8 Bil | |
ARGX
| argenx SE ADR | Sjtrdsprj | Gdr | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Tgtfgtrkl | Xvjm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jrjmkdfw | Stfrbs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ystspdn | Rfszph | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wzbgtcpjf | Bptxr | $12.5 Bil | |
INCY
| Incyte Corp | Qfztyyph | Grwvdv | $11.5 Bil |